Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension

Objective Overweight and heightened sympathetic activity are more common in hypertensive than normotensive subjects. β-adrenoceptor down-regulation has been described in hypertension. We tested the hypothesis that chronic sympathetic overactivity impairs β-adrenergic-mediated thermogenesis and thereby favours gain of weight in hypertension. Participants The study included 13 hypertensive subjects aged 35.3 ± 7.9 years and 25 normotensive subjects of control of similar age. Methods To measure β-adrenergically mediated haemodynamic, metabolic and thermogenic responsiveness, increasing doses of isoproterenol diluted in 2.5 ml saline were injected as intravenous boluses (0.1, 0.25, 0.5, 1.0 and 2.0 μg/m2). On a separate day, isoproterenol was infused continuously intravenously in increasing doses (10, 20 and 40 ng/kg per min), each dose for 30 min. Results The sitting heart rate and body mass were greater in hypertensives (P = 0.000, and P = 0.005, respectively). The heart rate responses to 1 and 2 μg/m2 isoproterenol bolus (P = 0.01 and P = 0.03, respectively) were reduced in hypertensives. The energy expenditure (P = 0.002) and oxygen consumption (P = 0.0004) increase with 40 ng/kg per min isoproterenol infusion, and glucose and phosphate responses at both 20 (P = 0.01 and P = 0.05) and 40 (P = 0.001 and P = 0.02) ng/kg per min isoproterenol infusion were attenuated in hypertensives. The baseline heart rate negatively correlated with heart rate (P = 0.015) response to isoproterenol bolus and blood pressure (P = 0.02) response to isoproterenol infusion. The urinary noradrenaline negatively correlated with heart rate response to isoproterenol bolus (P = 0.001), and with systolic blood pressure (P = 0.02) and energy expenditure responsiveness to isoproterenol infusion (P = 0.04). Furthermore, plasma noradrenaline negatively correlated with heart rate responsiveness to isoproterenol bolus (P = 0.004). Conclusions These results show a generalized decrease of β-adrenergic responsiveness in stage 1 hypertension and support the concept that sympathetic overactivity, via down-regulation of β-adrenoceptor-mediated thermogenic responses, may facilitate the development of obesity in hypertension.

[1]  G. Molenberghs,et al.  Longitudinal data analysis , 2008 .

[2]  Donald Hedeker,et al.  Longitudinal Data Analysis , 2006 .

[3]  T. Ogihara,et al.  Serum Uric Acid and Plasma Norepinephrine Concentrations Predict Subsequent Weight Gain and Blood Pressure Elevation , 2003, Hypertension.

[4]  J. Arch β3-Adrenoceptor agonists: potential, pitfalls and progress , 2002 .

[5]  S. Toubro,et al.  Acute effect of L‐796568, a novel β3‐adrenergic receptor agonist, on energy expenditure in obese men , 2002 .

[6]  L. Landsberg Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) , 2001, Journal of hypertension.

[7]  S. Toubro,et al.  Effects of the two β3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects , 2000, International Journal of Obesity.

[8]  R. Miller,et al.  Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. , 2000, Journal of medicinal chemistry.

[9]  S. Julius,et al.  Overweight and hypertension : a 2-way street? , 2000, Hypertension.

[10]  P. Arner Catecholamine-induced lipolysis in obesity , 1999, International Journal of Obesity.

[11]  E. Ravussin,et al.  Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. , 1998, Diabetes.

[12]  A. Strosberg,et al.  Desensitization of the β-Adrenergic Response in Human Brown Adipocytes. , 1998, Endocrinology.

[13]  S. Toubro,et al.  Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[14]  C. Stein,et al.  Forearm beta adrenergic receptor-mediated vasodilation is impaired, without alteration of forearm norepinephrine spillover, in borderline hypertension. , 1995, The Journal of clinical investigation.

[15]  S. Kjeldsen,et al.  Sympathetic Nervous System Involvement in Essential Hypertension: Increased Platelet Noradrenaline Coincides with Decreased β-Adrenoreceptor Responsiveness , 1994 .

[16]  A. Strosberg,et al.  The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. , 1993, Molecular pharmacology.

[17]  M. Dutia,et al.  Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent. , 1992, Journal of medicinal chemistry.

[18]  R. Schwartz,et al.  Reduced metabolic rate during β-adrenergic blockade in humans☆ , 1991 .

[19]  N. Schork,et al.  Hyperkinetic borderline hypertension in Tecumseh, Michigan , 1991, Journal of hypertension.

[20]  R. Feldman Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. , 1990, The Journal of clinical investigation.

[21]  I. Macdonald,et al.  Catecholamines and the control of metabolism in man. , 1985, Clinical science.

[22]  D. Robbins,et al.  Effects of Chronic β-Receptor Stimulation on Sympathetic Nervous System Activity, Energy Expenditure, and Thyroid Hormones , 1984 .

[23]  O. Bertel,et al.  Decreased Beta‐Adrenoreceptor Responsiveness as Related to Age, Blood Pressure, and Plasma Catecholamines in Patients with Essential Hypertension , 1980, Hypertension.

[24]  P. Kissinger,et al.  Determination of catecholamines in urine by reverse-phase liquid chromatography with electrochemical detection. , 1977, Analytical chemistry.

[25]  S. Julius,et al.  Mild high-renin essential hypertension. Neurogenic human hypertension? , 1977, The New England journal of medicine.

[26]  S. Julius,et al.  Altered Cardiac Responsiveness and Regulation in the Normal Cardiac Output Type of Borderline Hypertension , 1975, Circulation research.

[27]  F. Epstein,et al.  Overweight and Hypertension: A Review , 1969, Circulation.

[28]  W. Kannel,et al.  The relation of adiposity to blood pressure and development of hypertension. The Framingham study. , 1967, Annals of internal medicine.

[29]  J. B. Weir New methods for calculating metabolic rate with special reference to protein metabolism , 1949, The Journal of physiology.

[30]  Beretta-Piccoli,et al.  Plasma Catecholamines and Essential Hypertension An Analytical Review , 2005 .

[31]  A. Strosberg,et al.  Desensitization of the beta-adrenergic response in human brown adipocytes. , 1998, Endocrinology.

[32]  T. Ogihara,et al.  Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. , 1997, American journal of hypertension.

[33]  A. Hill,et al.  Serotoninergic modulation of the pattern of eating and the profile of hunger-satiety in humans. , 1987, International journal of obesity.

[34]  D. Robbins,et al.  Effects of chronic beta-receptor stimulation on sympathetic nervous system activity, energy expenditure, and thyroid hormones. , 1984, The Journal of clinical endocrinology and metabolism.